[Edaily Reporter Park Jung-Soo ] COPUS KOREA Co., Ltd.(322780)announced on the 29th that it has decided to conduct a third-party private placement worth 7.4999 billion won to secure operating funds. The company will issue a total of 5,716,461 common shares to Artist Studio, Jidam Media, and Storyark Studio, with the issue price set at 1,312 won per share (based on a reference share price of 1,457 won, representing a 10% discount). The new shares are scheduled to be listed on August 31.
Disclosure Plus
COPUS KOREA Co., Ltd. Decides on 7.5 Billion Won Capital Increase
Park Jung-Soo
2026-06-29 09:54:20
Economy
Corporation
IT·Science
Economy
Lisa Su Meets with Jeon Young-hyun for 3 Hours… “Broad Partnership” for Foundry Collaboration
Lisa Su, Chairwoman and CEO of AMD, concluded a meeting lasting over three hours with Jeon Young-hyun, President and CEO of SamsungElectronics and Vice Chairman in charge of the Device Solutions (DS) …
Corporation
South Korea Enters the 160 Trillion Global Obesity Drug Market… HanmiGlobal Co., Ltd’s “Epe” Becomes First Domestically Developed Drug to Receive Approval
Epfeglenatide, developed by HanmiPharm, has received approval from the Ministry of Food and Drug Safety as the first domestically developed GLP-1-based obesity treatment. With this approval, Korea has…
IT·Science
A Twist in the Story of the New Drug Rejected by Sanofi… Hanmi’s “Epe” Becomes the First Domestically Developed GLP-1 Weight-Loss Drug to Receive Approval
A new domestically developed drug has emerged to compete in the obesity treatment market, which is currently dominated by global pharmaceutical companies. With HanmiPharm’s efeglenatide receiving mark…
